CD200 immune checkpoint expression is associated with inferior outcome in multiple myeloma patients treated with anti-CD38 monoclonal antibodies

In multiple myeloma (MM), the anti-CD38 monoclonal antibody Daratumumab has become essential in the therapeutic arsenal, although very few predictive factors of response to Daratumumab have been identified in clinical studies. We have prospectively collected biological data from 97 patients treated...

Повний опис

Бібліографічні деталі

Автори:	Djamila Chemlal, Camille Pochard, Valentin Jacquier, Angélique Bruyer, Ludovic Gabellier, Léa Fornero, Clément Vempère, Amélie Machura, Guilhem Requirand, Nicolas Robert, Caroline Bret, Guillaume Cartron, Laure Vincent, Hugues de Boussac, Jérôme Moreaux, Charles Herbaux
Формат:	Artigo
Мова:	Inglês
Опубліковано:	Taylor & Francis Group 2025-12-01
Серія:	OncoImmunology
Предмети:	Myeloma immunotherapies resistance CD200
Онлайн доступ:	https://www.tandfonline.com/doi/10.1080/2162402X.2025.2532226
Теги:	Додати тег Немає тегів, Будьте першим, хто поставить тег для цього запису!